Takeda Acquires U.S. Biologics Manufacturing Facility from Baxalta

Takeda Pharmaceutical Company Limited

("Takeda") today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc

. Takeda intends to use the facility primarily for the manufacture of Entyvio® (vedolizumab) and other biologic products, allowing the company to maximize global efficiencies and further enhance the product's supply chain flexibility. "Takeda's focus is providing patients access to quality therapies," said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda. "Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global